Upstream Processing

Rentschler  brings single-use system online

Rentschler brings single-use system online

By Gareth Macdonald

Rentschler Biotechnologie has increased single-use bioreactor capacity at its manufacturing site in Laupheim, Germany and is moving forward with plans to invest €25m ($27m) in a new stainless steel system in the next few months.

CDMO Rottendorf signs five new projects with top biopharma companies

CDMO Rottendorf signs five new projects with top biopharma companies

By Zachary Brennan

Chicago-based Rottendorf Pharmaceuticals, a top 20 contract development and manufacturing organization (CDMO), has signed three formulation development projects and two commercial transfer projects with multiple top pharma and biotech companies in the...

(Image: R Nial Bradshaw)

UK R&D firm patents biologics powder storage technique

By Fiona BARRY

XstalBio, a private biopharma services company, has patented the use of stabilisers in the manufacture of dry powders for biopharmaceuticals – an alternative to freeze-drying or spray-drying techniques.

Horizon Discovery enters crowded CHO cell line market

Horizon Discovery enters crowded CHO cell line market

By Zachary Brennan

Horizon Discovery Group announced Monday that its bioproduction division has shipped its first commercially available engineered CHO (Chinese Hamster Ovary) cell line for use in manufacturing of antibodies. 

GEA spoke to Biopharma-Reporter at the Nuremberg Conference Centre yesterday

DISPATCHES FOM TECHNOPHARM, NUREMBERG

MAb production driving continuous fermentation, says GEA

By Dan Stanton

Development of continuous fermentation has been driven by the increased production of monoclonal antibodies says GEA, with Asia-Pacific the new growth driver for such technologies.

CMC Biologics to manufacture Zymeworks antibody

CMC Biologics to manufacture Zymeworks antibody

By Zachary Brennan

Contract manufacturer CMC Biologics and Zymeworks have entered into a master services agreement whereby CMC will perform the process development, formulation development and cGMP clinical manufacturing of a recombinant human IgG1 bi-specific (heterodimeric)...

ZMapp is produced with tobacco-plant based mAbs. (Picture: Kevin Bercaw)

CMO Kentucky Bioprocessing grows Ebola mAb from tobacco

By Fiona BARRY

ZMapp, the experimental Ebola therapy given to a handful of infected patients in West Africa, is being produced in tobacco plants for Mapp Biopharmaceutical by CMO Kentucky Bioprocessing in collaboration with drugmaker Defyrus.